Blood concentration and urinary excretion of captopril (SQ 14,225) in patients with chronic renal failure. 1981

K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara

Blood concentration and urinary excretion of captopril following 50 mg oral administration were determined by high-performance liquid chromatography in normal subjects and patients with chronic renal failure. In normal subjects, the maximum blood concentration of the free form of captopril was obtained within 1 hour and was not detectable after 6 hours; 41% of administered captopril was excreted into the urine as free form and metabolites within 2 hours, and 58% within 6 hours. In chronic renal failure patients with an average serum creatinine of 5.1 mg/dl, the absorption constant (Ka), maximum concentration (Cmax), and area under the blood concentration curve (AUC) were not significantly different from those in the normal subjects, but the elimination constant (Ke) and biological half-life (T1/2) showed a significant delay in the disappearance of captopril from the blood (p less than 0.01 respectively). The cumulative amount of urinary excretion of either free-form captopril or its' metabolites was significantly decreased at 2, 4, and 6 hours in chronic renal failure patients (p less than 0.01 or less, respectively). Impairment of kidney function is suggested to be an important factor in the promotion of blood retention of captopril.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
September 1985, Nihon Jinzo Gakkai shi,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
January 1985, Indian journal of dermatology, venereology and leprology,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
February 1981, Postgraduate medical journal,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
January 1988, Archives internationales de pharmacodynamie et de therapie,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
January 1987, Renal failure,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
December 1979, European journal of pharmacology,
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
May 1976, Polski tygodnik lekarski (Warsaw, Poland : 1960),
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
September 1976, Polski tygodnik lekarski (Warsaw, Poland : 1960),
K Onoyama, and H Hirakata, and K Iseki, and S Fujimi, and T Omae, and M Kobayashi, and Y Kawahara
October 1978, European journal of pharmacology,
Copied contents to your clipboard!